Hepatoblastoma clinical research: Lessons learned and future challenges

Pediatric Blood and Cancer

Volumn 59, Issue 5, 2012, Pages 818-821

  Perilongo, Giorgio ^a   Malogolowkin, Marcio ^b   Feusner, James ^c  

^a UNIVERSITY OF PADOVA   (Italy)

^b Medical College of Wisconsin ^*  (United States)

^c CHILDREN S HOSPITAL OAKLAND   (United States)

Author keywords

Chemotherapy for hepatoblastoma; PRETEXT system; Tumor resection

Indexed keywords

AMIFOSTINE; CARBOPLATIN; CISPLATIN; DOXORUBICIN; FLUOROURACIL; SODIUM THIOSULFATE; VINCRISTINE;

CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURGERY; CLINICAL RESEARCH; HEARING LOSS; HEPATOBLASTOMA; HUMAN; LIVER TRANSPLANTATION; LUNG METASTASIS; MULTIPLE CYCLE TREATMENT; OTOTOXICITY; PRIORITY JOURNAL; REVIEW;

ADOLESCENT; BIOMEDICAL RESEARCH; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; FEMALE; GERMANY; HEPATOBLASTOMA; HUMANS; INFANT; JAPAN; LIVER NEOPLASMS; MALE; MULTICENTER STUDIES AS TOPIC;

EID: 84866162300     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24217     Document Type: Review

References (21)

1. Ortega JA, Douglass EC, Feusner JH, et al. Randomized comparison of cisplatin/vincristine/fluorouracil and cisplatin/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: A report from the Children's Cancer Group and the Pediatric Oncology Group. J Clinic Oncol 2000; 18: 2665-2675.
2. Pritchard J, Brown J, Shafford E. et al. Cisplatin, doxorubicin, and delayed surgery for childhood hepatoblastoma: A successful approach-results of the first prospective study of the International Society of Pediatric Oncology. J Clin Oncol 2000; 18: 3819-3828.
3. von Schweinitz D, Byrd DJ, Hecker H. et al. Efficiency and toxicity of ifosfamide, cisplatin and doxorubicin in the treatment of childhood hepatoblastoma. Study Committee of the Cooperative Paediatric Liver Tumour Study HB89 of the German Society for Paediatric Oncology and Haematology. Eur J Cancer 1997; 33: 1243-1249.
4. Perilongo G, Maibach R, Shafford E, et al. Cisplatin versus cisplatin plus doxorubicin for standard risk hepatoblastoma. N Engl J Med 2009; 361: 1662-1670.
5. Tiao GM, Bobey N, Allen S, et al. The current management of hepatoblastoma: A combination of chemotherapy, conventional resection, and liver transplantation. J Pediatr 2005; 146: 204-211.
6. Malogolowkin MH, Katzenstein HM, Meyers RL, et al. Complete surgical resection is curative for children with hepatoblastoma with pure fetal histology: A report from the Children's Oncology Group. Clin Oncol 2011; 29: 3301-3306.
7. Zsíros J, Maibach R, Shafford E, et al. Successful treatment of childhood high risk hepatoblastoma with dose intensive multiagent chemotherapy and surgery-Final results of the SIOPEL-3HR study of the Childhood Liver Tumor Strategy Group. J Clin Oncol 2010; 28: 2584-2590.
8. Roebuck DJ, Aronson D, Clapuyt P, et al. 2005 PRETEXT: A revised staging system for primary malignant liver tumours of childhood developed by the SIOPEL group. International Childhood Liver Tumor Strategy Group. Pediatr Radiol 2007; 37: 123-132.
9. Brown J, Perilongo G, Shafford E, et al. Pretreatment prognostic factors for children with hepatoblastoma-Results from the International Society of Paediatric Oncology (SIOP) study SIOPEL 1. Eur J Cancer 2000; 36: 1418-1425.
10. Maibach R, Roebuck D, Brugieres L, et al. Prognostic stratification for children with hepatoblastoma: The SIOPEL experience. Eur J Cancer 2012; Jan 13. [Epub ahead of print].
11. Meyers RL, Rowland JR, Krailo M, et al. Predictive power of pretreatment prognostic factors in children with hepatoblastoma: A report from the Children's Oncology Group. Pediatr Blood Cancer 2009; 53: 1016-1022.
12. Perilongo G, Shafford E, Maibach R. et al. Risk-adapted treatment for childhood hepatoblastoma. Final report of the second study of the International Society of Paediatric Oncology-SIOPEL 2. Eur J Cancer 2004; 40: 411-421.
13. De Ioris M, Brugieres L, Zimmermann A, et al. Hepatoblastoma with a low serum alpha-fetoprotein level at diagnosis: The SIOPEL group experience. Eur J Cancer 2008; 44: 545-550.
14. Trobaugh-Lotrario AD, Tomlinson GE, Finegold MJ, et al. Small cell undifferentiated variant of hepatoblastoma: Adverse clinical and molecular features similar to rhabdoid tumors. Pediatr Blood Cancer 2009; 52: 328-334.
15. Malogolowkin MH, Katzenstein H, Krailo MD, et al. Intensified platinum therapy is an ineffective strategy for improving outcome in pediatric patients with advanced hepatoblastoma. J Clin Oncol 2006; 24: 2879-2884.
16. Perilongo G, Brown J, Shafford E, et al. Hepatoblastoma presenting with lung metastases: Treatment results of the first cooperative, prospective study of the International Society of Paediatric Oncology on childhood liver tumors. Cancer 2000; 89: 1845-1853.
17. Malogolowkin MH, Katzenstein HM, Krailo M. et al. Redefining the role of doxorubicin for the treatment of children with hepatoblastoma. J Clin Oncol 2008; 26: 2379-2383.
18. Otte JB, Pritchard J, Aronson DC, et al. Liver transplantation for hepatoblastoma: Results from the International Society of Pediatric Oncology (SIOP) study SIOPEL-1 and review of the world experience. International Society of Pediatric Oncology (SIOP). Pediatr Blood Cancer 2004; 42: 74-83. Review.
19. Otte JB. Progress in the surgical treatment of malignant liver tumors in children. Cancer Treat Rev 2010; 36: 360-371.
20. Katzenstein HM, Chang KW, Krailo M. et al. Amifostine does not prevent platinum-induced hearing loss associated with the treatment of children with hepatoblastoma: A report of the Intergroup Hepatoblastoma Study P9645 as a part of the Children's Oncology Group. Cancer 2009; 115: 5828-5835.
21. Koga Y, Matsukai A, Suminoe A, et al. Treatment-related acute myelomonocytic leukemia with t(11:19) in a child following chemotherapy for hepatoblastoma. Pediatr Blood Cancer 2008; 50: 943-944.